|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
TWI563002B
(en)
|
2007-09-26 |
2016-12-21 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region mutant
|
|
BRPI0817294A2
(pt)
|
2007-09-26 |
2015-03-17 |
Chugai Pharmaceutical Co Ltd |
Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
|
|
EP3056513A1
(en)
|
2008-04-11 |
2016-08-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20120071634A1
(en)
|
2009-03-19 |
2012-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Constant Region Variant
|
|
WO2010107110A1
(ja)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
JP5837821B2
(ja)
|
2009-09-24 |
2015-12-24 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
KR101398363B1
(ko)
|
2010-11-17 |
2014-05-22 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
|
KR102568454B1
(ko)
|
2010-11-30 |
2023-08-18 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
|
|
DK2668212T3
(en)
|
2011-01-28 |
2018-07-02 |
Saonofi Biotechnology |
HUMAN ANTIBODIES AGAINST PCSK9 FOR USE IN PROCEDURES FOR TREATING PARTICULAR GROUPS OF PERSONS
|
|
RU2608504C2
(ru)
|
2011-02-25 |
2017-01-18 |
Чугаи Сейяку Кабусики Кайся |
FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
|
|
MX340498B
(es)
|
2011-06-30 |
2016-07-11 |
Chugai Pharmaceutical Co Ltd |
Polipeptido heterodimerizado.
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
MY170089A
(en)
|
2011-09-16 |
2019-07-04 |
Regeneron Pharma |
Methods for reducing lipoproten(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
|
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
JP6124800B2
(ja)
|
2011-11-30 |
2017-05-10 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
|
|
SG10201704849PA
(en)
|
2012-02-09 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
EP2882778B1
(en)
|
2012-08-13 |
2018-04-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 antibodies with ph-dependent binding characteristics
|
|
TW202237660A
(zh)
|
2012-08-24 |
2022-10-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
|
EP2889376A4
(en)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
MOUSE FC RII SPECIFIC FC ANTIBODY
|
|
DK2940135T5
(da)
|
2012-12-27 |
2021-09-20 |
Chugai Pharmaceutical Co Ltd |
Heterodimeriseret polypeptid
|
|
LT2970497T
(lt)
*
|
2013-03-15 |
2018-03-12 |
Bayer Healthcare Llc |
Antikūno prieš tfpi variantai su skirtingu jungimusi ph intervale, skirti farmakokinetikos pagerinimui
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
WO2014163101A1
(ja)
|
2013-04-02 |
2014-10-09 |
中外製薬株式会社 |
Ｆｃ領域改変体
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
HK1222865A1
(zh)
|
2013-06-07 |
2017-07-14 |
Regeneron Pharmaceuticals, Inc. |
通过施用pcsk9抑制剂抑制动脉粥样硬化的方法
|
|
AU2014325063B2
(en)
|
2013-09-27 |
2019-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide heteromultimer
|
|
EP3068803B1
(en)
|
2013-11-12 |
2021-01-20 |
Sanofi Biotechnology |
Dosing regimens for use with pcsk9 inhibitors
|
|
MX379286B
(es)
|
2014-07-16 |
2025-03-10 |
Sanofi Biotechnology |
INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
EP3233921B1
(en)
*
|
2014-12-19 |
2021-09-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
|
EP4600372A3
(en)
|
2014-12-19 |
2025-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
KR102605798B1
(ko)
|
2015-02-05 |
2023-11-23 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
|
ES2973042T3
(es)
|
2015-03-31 |
2024-06-18 |
Sorriso Pharmaceuticals Inc |
Polipéptidos
|
|
CA2981103A1
(en)
*
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
WO2016156466A1
(en)
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Peptide construct having a protease-cleavable linker
|
|
WO2016159213A1
(ja)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN107614014B
(zh)
|
2015-05-28 |
2022-07-12 |
生物辐射实验室股份有限公司 |
亲和配体及其相关方法
|
|
CN106084058B
(zh)
*
|
2015-07-15 |
2019-08-27 |
北京天广实生物技术股份有限公司 |
抗人pcsk9单克隆抗体
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
|
CN106589127A
(zh)
|
2015-10-16 |
2017-04-26 |
钜川生物医药 |
一种pcsk9抗体及其制备方法和应用
|
|
TW202344514A
(zh)
*
|
2015-12-18 |
2023-11-16 |
日商中外製藥股份有限公司 |
抗c5抗體及使用方法
|
|
KR101820637B1
(ko)
*
|
2015-12-18 |
2018-01-19 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
|
EP3394098A4
(en)
|
2015-12-25 |
2019-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
|
|
CN108368166B
(zh)
|
2015-12-28 |
2023-03-28 |
中外制药株式会社 |
提高含fc区多肽纯化效率的方法
|
|
EP3401336A4
(en)
*
|
2016-01-05 |
2020-01-22 |
Jiangsu Hengrui Medicine Co., Ltd. |
ANTI-PCSK9 ANTIBODIES, ASSOCIATED ANTIGEN BINDING FRAGMENT, AND ASSOCIATED MEDICAL APPLICATION
|
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN105801701B
(zh)
*
|
2016-03-31 |
2019-03-29 |
河北仁博科技有限公司 |
一种pcsk9抗体的重链和轻链可变区及其应用
|
|
JP7320943B2
(ja)
|
2016-04-28 |
2023-08-04 |
中外製薬株式会社 |
抗体含有製剤
|
|
MY187848A
(en)
*
|
2016-06-17 |
2021-10-26 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
|
US11053308B2
(en)
|
2016-08-05 |
2021-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating IL-8-related diseases
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
WO2018139623A1
(en)
|
2017-01-30 |
2018-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-sclerostin antibodies and methods of use
|
|
MA49886A
(fr)
*
|
2017-03-16 |
2020-06-24 |
Medimmune Ltd |
Anticorps anti-par2 et leurs utilisations
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
|
GB201707484D0
(en)
|
2017-05-10 |
2017-06-21 |
Argenx Bvba |
Method of preparing ph-dependent antibodies
|
|
CN118878651A
(zh)
|
2017-07-06 |
2024-11-01 |
里珍纳龙药品有限公司 |
用于制备糖蛋白的细胞培养工艺
|
|
MX2020003472A
(es)
|
2017-11-01 |
2020-08-03 |
Chugai Pharmaceutical Co Ltd |
Variante e isoforma de anticuerpos con actividad biologica reducida.
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
KR102711151B1
(ko)
|
2017-12-22 |
2024-10-02 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 제품 불순물 특성화를 위한 시스템 및 방법
|
|
WO2019152303A1
(en)
|
2018-01-31 |
2019-08-08 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for characterizing drug product impurities
|
|
TW202311746A
(zh)
|
2018-02-02 |
2023-03-16 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
US12460270B2
(en)
|
2018-02-28 |
2025-11-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying viral contaminants
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
HUE065344T2
(hu)
|
2018-03-19 |
2024-05-28 |
Regeneron Pharma |
Mikrochip kapilláris elektroforézis assay-k és reagensek
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
KR102697702B1
(ko)
|
2018-08-10 |
2024-08-22 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
KR20210052389A
(ko)
|
2018-08-27 |
2021-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
다운스트림 정제에서의 라만 분광법의 사용
|
|
CN112601963B
(zh)
|
2018-08-30 |
2024-05-24 |
瑞泽恩制药公司 |
用于表征蛋白质复合物的方法
|
|
JP7445995B2
(ja)
*
|
2018-10-31 |
2024-03-08 |
バイオアトラ インコーポレイテッド |
抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
|
|
KR20210114926A
(ko)
|
2019-01-16 |
2021-09-24 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질 내에서 유리 티올을 식별하는 방법
|
|
HRP20241674T1
(hr)
|
2019-01-18 |
2025-02-14 |
Astrazeneca Ab |
6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
|
|
JP7720785B2
(ja)
|
2019-04-18 |
2025-08-08 |
ブリストル－マイヤーズ スクイブ カンパニー |
低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
|
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
|
EP3969475A4
(en)
|
2019-05-15 |
2023-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
An antigen-binding molecule, a pharmaceutical composition, and a method
|
|
WO2020236670A1
(en)
|
2019-05-17 |
2020-11-26 |
Regeneron Pharmaceuticals, Inc. |
Genome-based methods for reducing cardiovascular risk
|
|
KR20220064953A
(ko)
|
2019-06-21 |
2022-05-19 |
소리소 파마슈티컬스 인크. |
폴리펩티드
|
|
EP3986571A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
US12012451B2
(en)
*
|
2019-08-19 |
2024-06-18 |
The Rockefeller University |
Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
|
|
CN110669778A
(zh)
*
|
2019-09-19 |
2020-01-10 |
上海药明生物技术有限公司 |
一种对抗体pH依赖结合活性的快速改造及筛选方法
|
|
CA3150234C
(en)
|
2019-09-24 |
2023-12-12 |
Robert Stairs |
Systems and methods for chromatography use and regeneration
|
|
TWI832013B
(zh)
*
|
2019-09-30 |
2024-02-11 |
大陸商諾納生物（蘇州）有限公司 |
一種抗pd-l1抗原結合蛋白及其應用
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
WO2021108548A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
|
EP4354145B1
(en)
|
2020-01-21 |
2025-09-17 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
JP2023530997A
(ja)
*
|
2020-06-19 |
2023-07-20 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
|
|
AU2021332355A1
(en)
|
2020-08-31 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
|
US12239687B2
(en)
|
2020-11-25 |
2025-03-04 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
|
CN116710124A
(zh)
|
2020-12-17 |
2023-09-05 |
瑞泽恩制药公司 |
包封蛋白质的微凝胶的制造
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
US20220267415A1
(en)
*
|
2021-02-17 |
2022-08-25 |
The Board Of Regents Of The University Of Texas System |
Multimeric sars-cov-2 binding molecules and uses thereof
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
|
AU2022286340A1
(en)
|
2021-06-01 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
WO2023044139A1
(en)
|
2021-09-20 |
2023-03-23 |
Regeneron Pharmaceuticals, Inc. |
Methods of controlling antibody heterogeneity
|
|
MX2024004108A
(es)
|
2021-10-07 |
2024-04-19 |
Regeneron Pharma |
Calibracion y correccion de medidor de ph.
|
|
IL311245A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Systems and methods for pH modeling and control
|
|
JP2024541952A
(ja)
|
2021-10-26 |
2024-11-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
実験室用水を生成し、実験室用水を異なる温度で分配するためのシステム及び方法
|
|
EP4493921A1
(en)
|
2022-03-18 |
2025-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
|
US20240198253A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024158880A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
EP4669963A2
(en)
|
2023-02-22 |
2025-12-31 |
Regeneron Pharmaceuticals, Inc. |
SYSTEM FITNESS PARAMETERS AND COLUMN AGING
|
|
WO2024218743A1
(en)
|
2023-04-21 |
2024-10-24 |
Glycoera Ag |
Multi-functional molecules comprising glycans and uses thereof
|
|
AU2024265540A1
(en)
|
2023-05-01 |
2025-10-30 |
Regeneron Pharmaceuticals, Inc. |
Multidose antibody drug products using phenol or benzyl alcohol
|
|
WO2025054406A1
(en)
|
2023-09-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
|
WO2025064403A2
(en)
|
2023-09-18 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing chromatography protocols
|
|
US20250109905A1
(en)
|
2023-09-29 |
2025-04-03 |
Regeneron Pharmaceuticals, Inc. |
Lyophilization using controlled nucleation
|
|
US20250129117A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
US20250145662A1
(en)
|
2023-11-02 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|